litlas
Log inCreate account

Paul A. Marks

Active 1955–2013

Also published as
PAUL A. MARKS
82
Papers
24,812
Citations
81
h-index
82
i10-index

Citations

Citations per year for Paul A. Marks1966: 18 citations1967: 18 citations1968: 20 citations1969: 12 citations1970: 7 citations1971: 15 citations1972: 16 citations1973: 13 citations1974: 12 citations1975: 11 citations1976: 11 citations1977: 15 citations1978: 16 citations1979: 33 citations1980: 21 citations1981: 23 citations1982: 24 citations1983: 16 citations1984: 18 citations1985: 14 citations1986: 29 citations1987: 12 citations1988: 10 citations1989: 13 citations1990: 19 citations1991: 17 citations1992: 16 citations1993: 4 citations1994: 6 citations1995: 10 citations1996: 7 citations1997: 4 citations1998: 7 citations1999: 20 citations2000: 50 citations2001: 110 citations2002: 160 citations2003: 271 citations2004: 298 citations2005: 370 citations2006: 425 citations2007: 528 citations2008: 408 citations2009: 432 citations2010: 359 citations2011: 355 citations2012: 282 citations2013: 233 citations2014: 247 citations2015: 202 citations2016: 131 citations2017: 132 citations2018: 113 citations2019: 428 citations2020: 392 citations2021: 341 citations2022: 220 citations2023: 152 citations2024: 212 citations2025: 100 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,375 citing papers, 35.8% of this breakdownChina: 612 citing papers, 9.2% of this breakdownUnited Kingdom: 375 citing papers, 5.6% of this breakdownGermany: 341 citing papers, 5.1% of this breakdownItaly: 285 citing papers, 4.3% of this breakdownFrance: 219 citing papers, 3.3% of this breakdownJapan: 201 citing papers, 3% of this breakdownAustralia: 197 citing papers, 3% of this breakdownIndia: 192 citing papers, 2.9% of this breakdownCanada: 176 citing papers, 2.7% of this breakdownSouth Korea: 140 citing papers, 2.1% of this breakdownSpain: 114 citing papers, 1.7% of this breakdown
0%35.8%Other 21.3%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology65%
  • Medicine23.9%
  • Neuroscience4.8%
  • Immunology and Microbiology2.6%
  • Chemistry1%
  • Agricultural and Biological Sciences0.9%
  • Other1.8%

Topics

  • Histone Deacetylase Inhibitors Research17.2%
  • Protein Degradation and Inhibitors7.2%
  • Epigenetics and DNA Methylation6.8%
  • Peptidase Inhibition and Analysis3.8%
  • Ubiquitin and proteasome pathways2.6%
  • Autophagy in Disease and Therapy1.8%
  • Other60.6%

Coauthors

All papers

Open in search
  1. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

    Authors: Paul A. Marks, Ronald Breslow - Nature Biotechnology 2007 cited by 1,201

  2. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

    Authors: Michael S. Finnin, Jill R. Donigian, Alona Cohen, Victoria M. Richon, Richard A. Rifkind, Paul A. Marks, Ronald Breslow, Nikola P. Pavletich - Nature 1999 cited by 1,701

  3. Histone deacetylases and cancer: causes and therapies

    Authors: Paul A. Marks, Richard A. Rifkind, Victoria M. Richon, Ronald Breslow, Thomas A. Miller, William Kevin Kelly - Nature reviews. Cancer 2001 cited by 1,856

  4. Histone Deacetylase Inhibitors: Overview and Perspectives

    Authors: Milos Dokmanovic, Cathy Clarke, Paul A. Marks - Molecular Cancer Research 2007 cited by 1,158

  5. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

    Authors: Yufang Shao, Zhonghua Gao, Paul A. Marks, Xuejun Jiang - National Academy of Sciences, Proceedings of the National Academy of Sciences 2004 cited by 604

  6. Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylation

    Authors: Victoria M. Richon, Todd W. Sandhoff, Richard A. Rifkind, Paul A. Marks - National Academy of Sciences, Proceedings of the National Academy of Sciences 2000 cited by 1,097

  7. HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration

    Authors: Michał Mielcarek, Christian Landles, Andreas Weiss, Amyaouch Bradaïa, Tamara Seredenina, Linda Inuabasi, Georgina F Osborne, Kristian Wadel, Chrystelle Touller, Rachel Butler, Janette Robertson, Sophie Franklin, Donna L. Smith, Larry Park, Paul A. Marks, Erich E. Wanker, Eric N. Olson, Ruth Luthi‐Carter, Herman van der Putten, Vahri Beaumont, Gillian P. Bates - PLoS Biology 2013 cited by 170

  8. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases

    Authors: Victoria M. Richon, Stéphane Emiliani, Eric Verdin, Yael Webb, Ronald Breslow, Richard A. Rifkind, Paul A. Marks - National Academy of Sciences, Proceedings of the National Academy of Sciences 1998 cited by 914

  9. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

    Authors: Melissa J. Peart, Gordon K. Smyth, Ryan K. van Laar, David D.L. Bowtell, Victoria M. Richon, Paul A. Marks, Andrew J. Holloway, Ricky W. Johnstone - National Academy of Sciences, Proceedings of the National Academy of Sciences 2005 cited by 543

  10. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair

    Authors: J.-H. Lee, Megan L. Choy, Lang Ngo, Steven S. Foster, Paul A. Marks - National Academy of Sciences, Proceedings of the National Academy of Sciences 2010 cited by 378

  11. Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

    Authors: William Kevin Kelly, Owen A. O’Connor, Lee M. Krug, Judy H. Chiao, Mark Heaney, Tracy Curley, Barbara MacGregore-Cortelli, William P. Tong, J. Paul Secrist, Lawrence B. Schwartz, Stacy Richardson, Elaina Chu, Semra Olgac, Paul A. Marks, Howard I. Scher, Victoria M. Richon - Journal of Clinical Oncology 2005 cited by 907

  12. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

    Authors: Paul A. Marks - Expert Opinion on Investigational Drugs 2010 cited by 280

  13. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

    Authors: Emma Hockly, Victoria M. Richon, Benjamin Woodman, Donna L. Smith, Xianbo Zhou, Eddie Rosa, Kirupa Sathasivam, Shabnam Ghazi‐Noori, Amarbirpal Mahal, Philip A. S. Lowden, Joan S. Steffan, Joan Marsh, Leslie M. Thompson, Cathryn M. Lewis, Paul A. Marks, Gillian P. Bates - National Academy of Sciences, Proceedings of the National Academy of Sciences 2003 cited by 841

  14. Cloning and characterization of a histone deacetylase, HDAC9

    Authors: Xianbo Zhou, Paul A. Marks, Richard A. Rifkind, Victoria M. Richon - National Academy of Sciences, Proceedings of the National Academy of Sciences 2001 cited by 242

  15. Mechanisms of Resistance to Histone Deacetylase Inhibitors

    Authors: Ju‐Hee Lee, Megan L. Choy, Paul A. Marks - Advances in cancer research 2012 cited by 101

  16. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin

    Authors: Lisa M. Butler, Xianbo Zhou, Weisheng Xu, Howard I. Scher, Richard A. Rifkind, Paul A. Marks, Victoria M. Richon - National Academy of Sciences, Proceedings of the National Academy of Sciences 2002 cited by 508

  17. Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies

    Authors: Owen A. O’Connor, Mark Heaney, Lawrence B. Schwartz, Stacie Richardson, Robert D. Willim, Barbara MacGregor‐Cortelli, Tracey Curly, Craig H. Moskowitz, Carol S. Portlock, Steven M. Horwitz, Andrew D. Zelenetz, Stanley Frankel, Victoria M. Richon, Paul A. Marks, William Kevin Kelly - Journal of Clinical Oncology 2005 cited by 403

  18. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death

    Authors: Noor Gammoh, Du Lam, Cindy Puente, Ian G. Ganley, Paul A. Marks, Xuejun Jiang - National Academy of Sciences, Proceedings of the National Academy of Sciences 2012 cited by 210

  19. Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions

    Authors: Paul A. Marks - Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 2010 cited by 189

  20. SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease

    Authors: Michał Mielcarek, Caroline Benn, Sophie Franklin, Donna L. Smith, Ben Woodman, Paul A. Marks, Gillian P. Bates - PLoS ONE 2011 cited by 162

  21. Modulation of Renal Disease in MRL/lpr Mice by Suberoylanilide Hydroxamic Acid

    Authors: Christopher M. Reilly, Nilamadhab Mishra, Julie M. Miller, Dimple Joshi, Phillip Ruiz, Victoria M. Richon, Paul A. Marks, Gary S. Gilkeson - The Journal of Immunology 2004 cited by 146

  22. Development of a histone deacetylase 6 inhibitor and its biological effects

    Authors: Ju‐Hee Lee, Adaickapillai Mahendran, Yuanshan Yao, Lang Ngo, Gisela Venta-Perez, Megan L. Choy, Nathaniel Kim, Won Seok Ham, Ronald Breslow, Paul A. Marks - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 cited by 132

  23. Prospects: Histone deacetylase inhibitors

    Authors: Milos Dokmanovic, Paul A. Marks - Journal of Cellular Biochemistry 2005 cited by 479

  24. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.

    Authors: Pamela N. Münster, Tiffany A. Troso-Sandoval, Neal Rosen, Richard A. Rifkind, Paul A. Marks, Victoria M. Richon - 2001 cited by 374